For Clinical Trials
The Doctors Hospital at Renaissance Research Institute has clinical trials in the areas of Diabetes, Oncology and Cardiology that are actively recruiting qualified patients. For more detailed information about inclusion and exclusion criteria please contact the Research Department at (956) 362-2378, (956) 362-2379, or (956) 362-2381.
DIABETES: PEDIATRIC TRIALS
NOVO NORDISK 3659: Phase 3: Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycemic control in children and adolescents with type 2 diabetes
A 26-week double-blind, randomized, parallel group, placebo controlled multi-center trial followed by a 26-week open-label extension
DIABETES: ADULT TRIALS
DEPICT-TYPE 1 DIABETES: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus
CREDENCE TYPE 2 DIABETES WITH CHRONIC RENAL DISEASE: A Phase 3 Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy. The CREDENCE Trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial)
SPIRE DYSLIPIDEMIA: A PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS
VOYAGER Peripheral Artery Disease (PAD): An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.
MIA Multiply Myeloma Study: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy)
ADVANCE Breast Cancer Study: Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)
SHAVE2 Expansion at Renaissance: Surgery Based Study: A Multisite Randomized Control Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients.
AL16: Comparison of Two Human Milk Fortifiers in Preterm Infants.
DHR Health proudly meets the federal definition of a “physician-owned hospital” (42 CFR § 489.3). As required by law, a list of the hospital’s physician owners and investors is available at www.dhrhealth.com. DHR, Ltd. and its affiliated entities comply with applicable Federal civil rights laws and do not discriminate on the basis of race, color, national origin, age, disability, or sex.